Marker Therapeutics FY2024 net loss $10.7M; MT-601 78% response rate in lymphoma

Marker Therapeutics, Inc.

2025-Q1 EPS reported -$0.40 revenue$349,104

Net loss of $10.7M for FY2024 vs $8.2M in FY2023; R&D expense $13.5M, G&A $4.2M.
Cash and equivalents $19.2M at Dec 31, 2024; funds operations into Q1 2026 without additional grants.
Phase 1 APOLLO study: MT-601 (neldaleucel) achieved 78% objective response rate (7/9) with 44.4% complete responses; well-tolerated.
Secured $13M+ in non-dilutive funding from CPRIT ($9.5M) and NIH SBIR ($2M) for pancreatic and lymphoma programs.
December 2024 private placement raised $16.1M from new and existing investors including Blue Owl, NEA, Aisling Capital.

item 2.02 item 9.01

Machine-readable event card

schema_version: secwatch.filing_event.v1
accession: 0001104659-25-029666
form_type: 8-K
ticker: MRKR
cik: 0001094038
company_name: Marker Therapeutics, Inc.
filed_at: 2025-03-31T23:59:59+00:00
discovered_at: 2026-05-14T18:03:02.913163+00:00
generated_at: 2026-05-24T01:29:14.222305+00:00
sec_items: ["2.02", "9.01"]
event_type: earnings
sentiment: neutral
materiality_score: 0.7
confidence: high
secwatch_canonical_url: https://secwatch.observer/filing/0001104659-25-029666
json_url: https://secwatch.observer/filing/0001104659-25-029666.json
markdown_url: https://secwatch.observer/filing/0001104659-25-029666.md
text_url: https://secwatch.observer/filing/0001104659-25-029666.txt
edgar_index_url: https://www.sec.gov/Archives/edgar/data/1094038/000110465925029666/0001104659-25-029666-index.htm
edgar_primary_document_url: https://www.sec.gov/Archives/edgar/data/1094038/000110465925029666/tm2510813d1_8k.htm
generated_by_model: deepseek-v4-flash:cloud@v2
review_status: machine_generated
human_reviewed: false
corrected: false
correction_note: null
correction_timestamp: null
superseded_by: null

JSON Markdown Plain text

Source: SEC EDGAR

accession 0001104659-25-029666

view filing index on sec.gov

view primary document

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.